Relevance section written by JCO Associate Editor Suzanne Lentzsch, MD, PhD. Molecular risk reporting by the International Myeloma Working Group consensus 1 has so far been limited to the high-risk ...

Consistent diagnostic identification of high-risk disease is desirable to address unmet patient need. The aim was to investigate the consistency of association of co-occurrence of high-risk ...

Genetic testing should be used to help doctors spot high-risk cases of myeloma and enable targeted treatments, say researchers from the University of Leeds and The Institute of Cancer Research.

Nabsys 2.0, LLC (Nabsys) and Hitachi High-Tech America, Inc. (HTA) have revealed the awardees of their OhmX Rapid Application to Market Penetration User Partnership, or OhmX RAMP UP, Grant Program.

Medically reviewed by Marla Anderson, MD Multiple myeloma is a rare type of blood cancer that starts in your plasma cells.

In this article, we discuss the common reasons for recurrent fetal loss, plus diagnostic procedures to consider in pinpointing the problem, such as cytogenetic studies, blood coagulation protein ...

Offering state-of-the-art genetic testing to patients with the blood cancer myeloma would help doctors spot those with the most aggressive forms of the disease so that their cancer can be targeted ...